Depemokimab (GSK3511294) Market Analysis 2025-2035: Clinical Development, Therapeutic Scope, and Forecast Insights

Published: Nov, 2025
Report ID: GVR-MT-100487
Format: PDF/Excel databook

No. of Pages/Datapoints: 120
Report Coverage: 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
  1.2. Segment Definitions
  1.3. Estimates and Forecast Timeline
  1.4. Research Methodology
  1.5. Information Procurement
1.5.1. Purchased Database
  1.5.2. GVR’s Internal Database
  1.5.3. Secondary Sources
  1.5.4. Primary Research
  1.6. Information Analysis
  1.6.1. Data Analysis Models
  1.7. Market Formulation & Data Visualization
  1.8. Model Details
  1.8.1. Commodity Flow Analysis
  1.9. List of Secondary Sources
  1.10. Objectives
Chapter 2. Executive Summary
  2.1. Market Snapshot
  2.2. Segment Snapshot
  2.3. Competitive Landscape Snapshot
Chapter 3. Depemokimab Market Variables, Trends, & Scope
  3.1. Market Lineage Outlook
  3.2. Market Dynamics
  3.2.1. Market Driver Analysis
  3.2.2. Market Restraint Analysis
  3.3. Business Environment Analysis
  3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
  3.3.1.2. Buyer Power
  3.3.1.3. Substitution Threat
  3.3.1.4. Threat of New Entrants
  3.3.1.5. Competitive Rivalry
  3.3.2. PESTLE Analysis
  3.3.3. Pipeline Analysis
  3.3.4. Patent Expiry Analysis
  3.3.5. Pricing Analysis
Chapter 4. Depemokimab Market: Indication Business Analysis
  4.1. Indication Market Share, 2024 & 2033
  4.2. Indication Segment Dashboard
  4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  4.4. Severe Eosinophilic Asthma
  4.4.1. Severe Eosinophilic Asthma Market, 2021 - 2033 (USD Million)
  4.5. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  4.5.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Million)
  4.6. Other
  4.6.1. Other Market, 2021 - 2033 (USD Million)
Chapter 5. Depemokimab Market: Regional Estimates & Trend Analysis
  5.1. Regional Market Share Analysis, 2024 & 2033
  5.2. Regional Market Dashboard
  5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  5.4. North America
  5.5. Europe
  5.6. Asia Pacific
  5.7. Latin America
  5.8. Middle East and Africa
Chapter 6. Competitive Landscape
  6.1. Company Profile
  6.1.1. GSK plc
  6.1.1.1. Overview
  6.1.1.2. Financial Performance
  6.1.1.3. Product Benchmarking
  6.1.1.4. Strategic Mapping
  6.2. Concurrent Competitive Landscape
  6.2.1. AstraZeneca
  6.2.1.1. Overview
  6.2.1.2. Financial Performance
  6.2.1.3. Product Benchmarking
  6.2.1.4. Strategic Mapping
  6.2.2. Teva
  6.2.2.1. Overview
  6.2.2.2. Financial Performance
  6.2.2.3. Product Benchmarking
  6.2.2.4. Strategic Mapping
  6.2.3. Sanofi / Regeneron
  6.2.3.1. Overview
  6.2.3.2. Financial Performance
  6.2.3.3. Product Benchmarking
  6.2.3.4. Strategic Mapping
  6.2.4. Amgen / AstraZeneca
  6.2.4.1. Overview
  6.2.4.2. Financial Performance
  6.2.4.3. Product Benchmarking
  6.2.4.4. Strategic Mapping
  6.2.5. Eli Lilly
  6.2.5.1. Overview
  6.2.5.2. Financial Performance
  6.2.5.3. Product Benchmarking
  6.2.5.4. Strategic Mapping

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Depemokimab market, by region, 2021 - 2033 (USD Million)
Table 4 North America Depemokimab market, by Indication, 2021 - 2033 (USD Million)
Table 5 Europe Depemokimab market, by Indication, 2021 - 2033 (USD Million)
Table 6 Asia Pacific Depemokimab market, by Indication, 2021 - 2033 (USD Million)
Table 7 Latin America Depemokimab market, by Indication, 2021 - 2033 (USD Million)
Table 8 Middle East & Africa Depemokimab market, by Indication, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Depemokimab market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and disease outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Depemokimab market dynamics
Fig. 12 Depemokimab market: Porter’s five forces analysis
Fig. 13 Depemokimab market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Depemokimab market revenue, by region
Fig. 16 Regional marketplace: Key takeaways
Fig. 17 North America Depemokimab market, 2021 - 2033 (USD Million)
Fig. 18 Europe Depemokimab market, 2021 - 2033 (USD Million)
Fig. 19 Asia Pacific Depemokimab market, 2021 - 2033 (USD Million)
Fig. 20 Latin America Depemokimab market, 2021 - 2033 (USD Million)
Fig. 21 MEA Depemokimab market, 2021 - 2033 (USD Million)
Fig. 22 Company categorization
Fig. 23 Company market position analysis
Fig. 24 Strategic framework

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.